ClinicaliQ Trial Snapshot
- Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Severe Active GPA or MPA — Recruiting • Phase II • Cardiology / Cardiovascular • NCT06868290.
- Treatment being tested: Rapcabtagene autoleucel, a CAR-T cell therapy, is being evaluated against a comparator treatment in patients with severe active GPA or MPA—rare systemic vasculitides that cause significant organ damage and mortality if untreated.
- Patient eligibility overview: The trial targets patients with documented severe active Granulomatosis with Polyangiitis or Microscopic Polyangiitis; specific inclusion/exclusion criteria would typically address disease activity markers, organ involvement, prior treatment history, and performance status.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel versus comparator in participants with severe active Granulomatosis with Polyangiitis (GPA) or Microscopic Polyangiitis (MPA)
Eligibility Snapshot
- Key inclusion criteria: 1. Men and women, aged ≥18 and ≤ 75 years with a diagnosis of GPA or MPA according to the American College of Rheumatology/ European League Against Rheumatism 2022 (ACR/EULAR 2022) classification criteria 2. Positive test for ANCA-autoantibodies 3. GPA and MPA participants with severe active disease Key
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.